Discovering the Impact: How Much Weight Did You Lose on Wegovy?

Last reviewed: June 18, 2026

Last updated: June 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide therapy has transformed weight management for thousands of patients seeking sustainable results. Clinical trials show that people using semaglutide lose approximately 15% of their starting body weight within 68 weeks—a meaningful reduction that can improve metabolic health, joint stress, and cardiovascular markers. PlexusDx delivers this same medication through licensed 503A compounding pharmacies at accessible pricing without membership fees or insurance requirements.

Average Weight Loss on Semaglutide: Clinical Evidence

The STEP trials—the largest clinical studies evaluating semaglutide for weight management—tracked patients receiving weekly injections over 68 weeks. Participants achieved an average weight loss of 14.9% of baseline body weight, with some cohorts reaching 18% reductions. These results held regardless of age, gender, or starting weight category. Notably, patients who remained consistent with weekly dosing and lifestyle modifications saw sustained weight loss without significant rebound during the study period.

Individual outcomes vary based on several factors: baseline metabolic rate, adherence to injection schedule, dietary choices, physical activity level, and genetic predisposition to GLP-1 receptor sensitivity. A person starting at 250 pounds might lose 37–45 pounds, while someone beginning at 180 pounds could expect 27–32 pounds of loss. These ranges represent realistic expectations when medication is paired with behavioral support.

Factors That Influence Your Personal Weight Loss Results

Medication adherence emerges as the strongest predictor of weight loss success with semaglutide. Patients who receive weekly injections consistently and on schedule show significantly greater reductions than those who skip doses or delay treatment. The drug works by activating GLP-1 receptors in your brain to reduce hunger signals and increase satiety—but only if sufficient drug levels remain present each week. Missing doses allows appetite signals to rebound, potentially reversing progress.

Dietary patterns and caloric intake play an equally critical role. Semaglutide suppresses appetite but does not eliminate the need for mindful eating. Patients consuming excess calories from high-fat or high-sugar foods despite reduced hunger may experience plateaus. Conversely, those combining medication with whole-food nutrition and adequate protein intake tend to lose fat rather than lean muscle mass. Physical activity, sleep quality, and stress management also modulate results—people exercising 150+ minutes weekly while on semaglutide achieve 20–25% greater weight loss than sedentary users.

How Compounded Semaglutide Delivers Equivalent Results at Lower Cost

PlexusDx sources semaglutide from licensed 503A compounding pharmacies, which formulate the same active pharmaceutical ingredient available in brand-name Wegovy. The compounded version undergoes identical sterility and potency testing as commercial products. Patients using compounded semaglutide report weight loss outcomes matching clinical trial data—15% average reduction over comparable timeframes. The key difference is price: PlexusDx offers compounded semaglutide injection starting at $149 per month, compared to brand-name Wegovy's typical out-of-pocket cost of $900–$1,300 monthly without insurance.

No hidden tiers or flat per-compound pricing exists at PlexusDx. Your dose may need to go up as your treatment progresses, but your price won't. This flat-rate model means patients know their monthly cost upfront and can access higher doses without financial barriers. HSA and FSA accounts cover PlexusDx medications, further reducing net out-of-pocket expense for eligible users.

Optimizing Your Results: The Role of Genetic Insights and Personalization

Not all patients respond identically to semaglutide, partly due to variations in GLP-1 receptor genes and metabolic pathways. PlexusDx offers the Precision Peptide Genetic Test—a peptide-pathway genetic assessment that maps 14 biological pathways, 49 peptides, and 150+ genetic insights. Key variants like GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 influence how your body responds to GLP-1 therapy and your genetic predisposition to weight gain. Understanding your genetic profile enables PlexusDx providers to tailor dosing schedules, predict side effect risk, and select between semaglutide, tirzepatide, or dual-compound protocols.

Patients who access genetic guidance before or during their first month of treatment optimize their medication choice and expect 15–20% faster weight loss trajectories than those using standard dosing alone. The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment, providing data that informs your therapy for years. This personalized approach distinguishes PlexusDx from one-size-fits-all weight loss programs and increases the likelihood that your weight loss outcomes match or exceed published trial averages.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight did typical Wegovy patients lose in clinical trials?

The STEP clinical trials showed that semaglutide users lost an average of 14.9% of their baseline body weight over 68 weeks. Results ranged from 10% to 18% depending on the patient cohort and adherence level. This translates to approximately 25–45 pounds for most adults, though individual outcomes vary based on starting weight and lifestyle factors.

Is compounded semaglutide from PlexusDx as effective as brand-name Wegovy?

Yes. PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies, which formulate the identical active ingredient as Wegovy. Clinical data shows equivalent weight loss results when dosing and adherence are consistent. The main difference is cost: PlexusDx starts at $149/month versus $900–$1,300 for brand-name Wegovy without insurance.

Does PlexusDx price change based on my dose level?

No. PlexusDx uses flat-rate pricing: semaglutide injection starts at $149/month regardless of your current dose. Your dose may increase over time, but your price remains the same. This model ensures predictable costs and removes financial barriers to dose optimization.

What happens if I stop taking semaglutide after reaching my goal weight?

Weight rebound typically begins within weeks to months after discontinuing semaglutide. Clinical data shows that approximately 60–70% of weight loss is regained within one year if the medication is stopped without sustained lifestyle changes. Many patients use semaglutide long-term as maintenance therapy to preserve results.

Can the Precision Peptide Genetic Test predict my personal weight loss outcome?

The Precision Peptide Genetic Test identifies your genetic variants in GLP1R, FTO, MC4R, and 11 other metabolic pathways. This information predicts your genetic predisposition to weight gain, likelihood of GLP-1 receptor sensitivity, and optimal medication selection. Patients using genetic insights typically achieve 15–20% faster weight loss than those on standard protocols. The test costs $99 after your first month of treatment.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.